Last week, 7 pharmaceutical and biological companies disclosed their performance reports!

Last week (March 7-13), another batch of pharmaceutical and biological companies disclosed their 2021 performance reports, including seven companies including Jidan Bio, Yuexin Health, and China Resources Sanjiu, whose fields involved in vitro diagnosis, medical services, In traditional Chinese medicine, CRO and other industries, the performance of most companies is basically good news
.
Last week, 7 pharmaceutical and biological companies disclosed their performance reports! Good news for 6 companies (Source: Pharmaceutical Network) Jidan Bio: Net profit increased by 28.
66% year-on-year The performance report disclosed by Jidan Bio on the evening of March 11 shows that the company's operating income in 2021 will be 1.
372 billion yuan, a year-on-year increase of 22.
09%; The profit was 392 million yuan, a year-on-year increase of 28.
66%; the basic earnings per share was 1.
08 yuan
.
Regarding the reasons for the increase in performance, the company stated that during the reporting period, domestic medical institutions gradually resumed normal operation, and the sales of the company's self-produced products increased
.
According to public information, the company specializes in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments
.
Yuexin Health: Net profit decreased by 19.
27% ​​year-on-year.
On March 11, Yuexin Health released the 2021 annual performance report.
The company achieved a total operating income of 1.
261 billion yuan, a year-on-year increase of 5.
54%; the net profit attributable to shareholders of the listed company was 46.
171 million yuan.
A year-on-year decrease of 19.
27%
.
The company stated that during the reporting period, the company's building materials business was affected by the state's regulation on the financial and credit policies of the real estate industry, resulting in intensified market competition and sluggish sales prices.
In addition, it was also affected by many factors such as dual carbon and dual control policies, power and production restrictions, and rising energy and raw material prices.
As a result, the gross profit margin of the company's ceramic tile business decreased.
Although operating income increased slightly, operating profit decreased
.
According to the data, Yuexin Health, formerly known as Smike, was established in 1993, listed in 2007, and changed its name to Yuexin Health after transforming into the field of general health in 2015
.
Its businesses include building materials business, medical services, elderly care services, investment real estate leasing, etc.

.
China Resources Sanjiu: Net profit increased by 28.
13% year-on-year.
On the evening of March 11, China Resources Sanjiu released its 2021 annual performance report, achieving a total operating income of 15.
320 billion yuan, a year-on-year increase of 12.
34%; net profit attributable to the parent of 2.
047 billion Yuan, a year-on-year increase of 28.
13%
.
The main reason for the increase in performance is the steady growth of the company's overall operating trend, and the increase in the proportion of revenue from the CHC segment with strong profitability; at the same time, goodwill impairment is accrued in 2020, and the profit base is slightly lower
.
Statistics show that CR Sanjiu focuses on innovative R&D and intelligent manufacturing of high-quality medical and health products, promotes high-quality development, and serves every member of the Chinese family
.
Sunshine: Net profit increased by 106.
91% year-on-year.
On March 10, the 2021 annual performance report disclosed by Sunshine showed that the company's total operating income in 2021 was 12.
798 billion yuan, an increase of 23.
40% over the same period last year; the net profit attributable to shareholders of listed companies The profit was 860 million yuan, an increase of 106.
91% over the same period of the previous year
.
The growth of the company's performance is inseparable from the company's grasp of market opportunities.
Through deepening internal reforms, it actively reduces costs and increases efficiency, and enhances the efficiency of production, sales and research
.
According to the data, the main business of Dongguang Sunshine includes four major sectors: electronic new materials, alloy materials, chemical products, and pharmaceutical manufacturing
.
Antu Bio: Net profit increased by 30.
21% year-on-year Antu Bio released the 2021 annual performance report on the evening of March 9.
In 2021, the company achieved operating income of 3.
767 billion yuan, a year-on-year increase of 26.
48%; net profit attributable to the parent was 974 million yuan, a year-on-year increase of 3.
021% %
.
The increase in performance was mainly due to the effective prevention and control of the domestic epidemic in 2021, the recovery of outpatient visits in hospitals compared with the same period in 2020, and the increase in sales of the company's magnetic particle chemiluminescence detection reagents
.
According to public information, Antu Bio is a company specializing in the research and development, production and sales of in vitro diagnostic reagents and instruments.

.
Tigermed: Net profit increased by 64.
26% year-on-year Tigermed released the 2021 annual performance announcement on March 10.
The announcement shows that the company's total operating income in 2021 will be 5.
214 billion yuan, a year-on-year increase of 63.
32%; net profit will be 2.
874 billion yuan, A year-on-year increase of 64.
26%
.
In addition, during the reporting period, the non-recurring profit and loss attributable to shareholders of the listed company was 1.
643 billion yuan, mainly due to the company's investment in biomedicine, medical equipment and other companies related to the company's main business and financial assets of medical and health professional investment funds.
This is due to the increase in gains from changes in the fair value of financial assets recognized by the Financial Instruments Standards and gains from equity transfer
.
According to the data, Tigermed is a contract research organization (CRO) that focuses on providing professional services for the whole process of clinical trials for new drug research and development, and provides comprehensive and comprehensive clinical research solutions for global pharmaceutical and medical device innovation companies
.
Zuoli Pharmaceutical: Net profit increased by 101.
28% year-on-year Zuoli Pharmaceutical released the 2021 annual performance report on the evening of March 9.
During the reporting period, the company achieved operating income of 1.
457 billion yuan, an increase of 33.
60% over the same period last year; net profit of 179 million Yuan, an increase of 101.
28% over the same period of the previous year
.
At the same time, Zuoli Pharmaceutical also released a performance forecast for the first quarter of 2022.
It is expected to achieve a net profit of 67 million yuan to 71 million yuan in the first quarter of this year, an increase of 52.
98% to 62.
12% over the same period last year
.
Regarding the reasons for the growth in performance, the company stated that there are two aspects: first, the operating income of the main products Wuling Capsules, Bailing Tablets and Lingze Tablets have achieved rapid growth; second, the company's profitability has improved and the amount of funds is more abundant.
, the loan scale has been reduced, and the burden of financial expenses has been further reduced
.
According to the data, Zuoli Pharmaceutical's main business includes research and development, production, marketing and service of medicinal fungus series products and APIs, Chinese herbal decoction pieces, and Chinese herbal formula granules
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.